-
-
-
-
-
-
-
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2026
-
-
-
-
-
-
-
Aditxt Weekly Update to Highlight Recent Events, Including Regaining Compliance with Nasdaq Listing Requirements
-
-
-
-
-
-
-
Aditxt, Inc (ADTX) Subsidiary Adimune to Ship Drug Substances for Final Drug Product Formulation of ADI-100
-
-
-
-
-
-
-
Aditxt's Subsidiary Adimune Successfully Completes Preclinical Efficacy and Safety Studies for Its Immune Modulation Therapeutic ADI Platform, Advancing Toward First-in-Human Clinical Trials
-
-
-
-
-
-
-
Aditxt To Host Virtual Stakeholder Update and Q&A Session on Friday, November 1, 2024, at 11:30 AM Eastern Time
-
-
-
-
-
-
-
Aditxt Completes Third Parent Equity Investment Under Amended and Restated Merger Agreement With Evofem
-
-
-
-
-
-
-
Aditxt (ADTX) Subsidiary Pearsanta Submits a Grant Application Seeking to Advance Clinical Trials for MitomicĀ® Prostate Test, Targeting Early Detection in High-Risk Patients
-
1,168,813 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

